Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone732-537-6200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.52 billion
Profitability
Miscellaneous
Employees12,300
Next Earnings Date2/3/2020 (Confirmed)
OptionableOptionable
Catalent (NYSE:CTLT) Frequently Asked Questions
What is Catalent's stock symbol?
Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."
How were Catalent's earnings last quarter?
Catalent Inc (NYSE:CTLT) issued its quarterly earnings results on Tuesday, November, 5th. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.19 by $0.07. The company earned $664.70 million during the quarter, compared to the consensus estimate of $634.87 million. Catalent had a return on equity of 15.30% and a net margin of 5.77%. Catalent's revenue was up 20.5% on a year-over-year basis. During the same period last year, the company earned $0.28 earnings per share. View Catalent's Earnings History.
When is Catalent's next earnings date?
How can I listen to Catalent's earnings call?
Catalent will be holding an earnings conference call on Monday, February 3rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What price target have analysts set for CTLT?
6 brokerages have issued 1-year price targets for Catalent's shares. Their forecasts range from $49.00 to $64.00. On average, they anticipate Catalent's share price to reach $58.67 in the next year. This suggests that the stock has a possible downside of 4.7%. View Analyst Price Targets for Catalent.
What is the consensus analysts' recommendation for Catalent?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalent.
Has Catalent been receiving favorable news coverage?
Press coverage about CTLT stock has been trending very positive on Friday, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Catalent earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Catalent.
Are investors shorting Catalent?
Catalent saw a decrease in short interest in December. As of December 31st, there was short interest totalling 4,610,000 shares, a decrease of 6.5% from the December 15th total of 4,930,000 shares. Based on an average daily volume of 651,000 shares, the short-interest ratio is currently 7.1 days. Currently, 3.2% of the company's shares are short sold. View Catalent's Current Options Chain.
Who are some of Catalent's key competitors?
Some companies that are related to Catalent include ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), UCB (UCBJF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA) and Bausch Health Companies (BHC).
What other stocks do shareholders of Catalent own?
Who are Catalent's key executives?
Catalent's management team includes the folowing people:
- Mr. John R. Chiminski, Chairman & CEO (Age 55)
- Mr. Wetteny N. Joseph, Sr. VP & CFO (Age 47)
- Mr. Steven L. Fasman, Sr. VP, Gen. Counsel & Corp. Sec. (Age 56)
- Mr. Jonathan Arnold, Pres of Oral Drug Delivery Bus. Unit (Age 53)
- Mr. Alessandro Maselli, Pres & COO (Age 47)
Who are Catalent's major shareholders?
Catalent's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Ironvine Capital Partners LLC (0.19%), Norris Perne & French LLP MI (0.14%), Global Thematic Partners LLC (0.09%), Mountain Pacific Investment Advisers Inc. ID (0.08%), New York State Teachers Retirement System (0.05%) and Three Peaks Capital Management LLC (0.04%). Company insiders that own Catalent stock include Alessandro Maselli, Aristippos Gennadios, Barry Littlejohns, Donald E Morel, Jr, Gregory T Lucier, John J Greisch, John R Chiminski, Lance Miyamoto, Michael J Grippo, Peter L Buzy, Ricardo Pravda, Steven L Fasman and William Downie. View Institutional Ownership Trends for Catalent.
Which major investors are selling Catalent stock?
CTLT stock was sold by a variety of institutional investors in the last quarter, including Campbell & CO Investment Adviser LLC, State of Alaska Department of Revenue and We Are One Seven LLC. Company insiders that have sold Catalent company stock in the last year include Alessandro Maselli, Aristippos Gennadios, Barry Littlejohns, John R Chiminski, Lance Miyamoto, Michael J Grippo, Ricardo Pravda, Steven L Fasman and William Downie. View Insider Buying and Selling for Catalent.
Which major investors are buying Catalent stock?
CTLT stock was bought by a variety of institutional investors in the last quarter, including Three Peaks Capital Management LLC, Global Thematic Partners LLC, Nisa Investment Advisors LLC, McGuire Investment Group LLC, AdvisorShares Investments LLC, Mountain Pacific Investment Advisers Inc. ID, Strs Ohio and Ironvine Capital Partners LLC. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr, Gregory T Lucier, John J Greisch and Peter L Buzy. View Insider Buying and Selling for Catalent.
How do I buy shares of Catalent?
Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Catalent's stock price today?
One share of CTLT stock can currently be purchased for approximately $61.58.
How big of a company is Catalent?
Catalent has a market capitalization of $9.01 billion and generates $2.52 billion in revenue each year. The company earns $137.40 million in net income (profit) each year or $1.62 on an earnings per share basis. Catalent employs 12,300 workers across the globe.View Additional Information About Catalent.
What is Catalent's official website?
How can I contact Catalent?
Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]
MarketBeat Community Rating for Catalent (NYSE CTLT)
MarketBeat's community ratings are surveys of what our community members think about Catalent and other stocks. Vote "Outperform" if you believe CTLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTLT will underperform the S&P 500 over the long term. You may vote once every thirty days.
